LEXINGTON, KY (July 1, 2014) – The June 24 announcement by the British Horseracing Authority (BHA) of its enhanced, zero-tolerance policy toward the use of anabolic steroids has generated a response from the Keeneland Association and Fasig-Tipton Company Inc. about the integrity of Thoroughbreds sold by major American sales companies.
“U.S. sales companies have been at the forefront of this issue,” said Bill Thomason, President of Keeneland Association. “In November 2007, Keeneland and Fasig-Tipton became the first Thoroughbred auction companies anywhere in the world to announce the implementation of a policy regarding the use of exogenous anabolic steroids in sales yearlings beginning in 2008.”
“Keeneland and Fasig-Tipton were the first to initiate testing for anabolic steroids and the first to fund extensive research to determine threshold levels for androgenous anabolic steroids,” said Boyd T. Browning, President of Fasig-Tipton Company. “Thousands of yearlings have been sold since the inception of this policy, and there has not been a single positive test for anabolic steroids.”
In 2007, Keeneland and Fasig-Tipton formed a committee comprising representatives from the two sales companies, the Consignors and Commercial Breeders Association (CBA), leading veterinarians and prominent authorities on steroids and drug testing in the U.S. to establish a policy regarding sale horses.
In December 2007, the Ocala Breeders’ Sales Company announced a similar procedure would be available starting with its 2-year-olds in training sale in February 2008.
In 2011, after extensive research, the sales companies expanded their available testing for buyers to include androgenous anabolic steroids.